Population-based testing for BRCA 1/2 gene mutations detects the high proportion of carriers not identified by cancer family history (FH)-based testing. A new study published in the Journal of the … Continued
A special message from OCRF Founder and Chair, Sol Schreiber.
Genentech, a member of the Roche Group today announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with chemotherapy for the treatment of women with … Continued
The combination of the antiangiogenesis drug bevacizumab and the vascular-disrupting agent fosbretabulin is superior to bevacizumab alone in the treatment of recurrent ovarian, tubal, and peritoneal cancer, according to an … Continued
Amgen Inc said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial. Patients given the drug, trebananib, along with a chemotherapy … Continued
According to a new study published in the Journal of the National Cancer Institute, a good diet before diagnosis is linked with lower mortality among ovarian cancer survivors. Researchers analyzed … Continued
There have been widespread efforts to improve the quality of life of terminally ill patients. As more patients choose to spend their final days and weeks in hospice care rather … Continued
Telomeres are essential for the maintenance of chromosomal integrity. Telomere shortening leads to genomic instability, which is hypothesized to play a role in cancer development and prognosis. New data published … Continued
(October 14, 2014) In a pilot study published in the journal Obstetrics & Gynecology, researchers detected DNA derived from tumor cells in the vaginas of 60% of patients with ovarian … Continued
(October 6, 2014) A research team based at the University of Pennsylvania mined junk DNA sequences to identify a non-protein-coding RNA whose expression is linked to ovarian cancer. The study, … Continued
(Sept. 29, 2014) In a perspective piece for the website MedPage Today, representatives from the Society of Gynecologic Oncology discuss clinical endpoints appropriate for studies addressing the “unique characteristics” of … Continued
(Sept. 25, 2014) Maintenance therapy with the oral agent pazopanib improved progression free survival (PFS) by a median of 5.6 months in patients with advanced ovarian cancer but did not … Continued
Get email updates about research news, action alerts, and ways to join the fight.
